ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,658.64
      0.49%
      US Tech 100
      19,794.80
      -0.26%
      Dow Jones
      40,882.75
      1.67%
      Brent Oil
      83.125
      -1.44%
      Bitcoin
      64,668.55
      -0.28%
      Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Mainz BioMed NV (MYNZ)

      7. Mainz BioMed NV (MYNZ) News

      MYNZ

      Mainz BioMed NV (MYNZ)

      Mainz BioMed NV
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:MYNZ
      DateTimeSourceHeadlineSymbolCompany
      05/16/20233:01AMGlobeNewswire Inc.Mainz Biomed Announces First Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:MYNZMainz BioMed NV
      05/10/20233:01AMGlobeNewswire Inc.Mainz Biomed Partners with Microba Life Sciences for the Development of PancAlertNASDAQ:MYNZMainz BioMed NV
      05/03/20233:01AMGlobeNewswire Inc.Mainz Biomed Announces Addition of Eurofins GeLaMed to its Growing Network of Lab PartnersNASDAQ:MYNZMainz BioMed NV
      05/01/20233:01AMGlobeNewswire Inc.Mainz Biomed to Participate in Digestive Disease Week 2023NASDAQ:MYNZMainz BioMed NV
      04/27/20233:01AMGlobeNewswire Inc.Mainz Biomed to Commence Quarterly Reporting and Present at Equity Forum Spring Conference 2023 in Frankfurt, GermanyNASDAQ:MYNZMainz BioMed NV
      04/26/20233:01AMGlobeNewswire Inc.Mainz Biomed Announces Partnership with the Instituto de Microecologia to Expand ColoAlert® Commercialization in Spain and PortugalNASDAQ:MYNZMainz BioMed NV
      04/10/20233:01AMGlobeNewswire Inc.Mainz Biomed Provides Full Year 2022 Financial ResultsNASDAQ:MYNZMainz BioMed NV
      04/07/20234:46PMEdgar (US Regulatory)Annual and Transition Report (foreign Private Issuer) (20-f)NASDAQ:MYNZMainz BioMed NV
      04/04/20233:01AMGlobeNewswire Inc.Mainz Biomed Expands Corporate Health Program for ColoAlert with the Addition of Three New Companies in GermanyNASDAQ:MYNZMainz BioMed NV
      03/29/20233:01AMGlobeNewswire Inc.Mainz Biomed Reports Positive Results from Feasibility Study Evaluating its Portfolio of Novel mRNA Biomarkers for Early Detection of Advanced Colorectal AdenomasNASDAQ:MYNZMainz BioMed NV
      03/21/20233:01AMGlobeNewswire Inc.Mainz Biomed to Present at Sidoti Virtual Investor Conference March 22-23NASDAQ:MYNZMainz BioMed NV
      03/15/20233:01AMGlobeNewswire Inc.Mainz Biomed Announces Partnership with Labor Staber to Expand ColoAlert Commercialization in GermanyNASDAQ:MYNZMainz BioMed NV
      03/08/20233:01AMGlobeNewswire Inc.Mainz Biomed Launches Number of Educational Events in Germany to Raise Awareness for CRC Screening and Early DetectionNASDAQ:MYNZMainz BioMed NV
      03/01/20233:01AMGlobeNewswire Inc.Mainz Biomed Recognizes Colorectal Cancer Awareness Month Throughout “Blue” March 2023NASDAQ:MYNZMainz BioMed NV
      02/28/20238:01AMGlobeNewswire Inc.Mainz Biomed to Appear on ClearThink IR’s Virtual Live Event on Wednesday, March 1, 2023 at 12 Noon ETNASDAQ:MYNZMainz BioMed NV
      02/21/20238:02AMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:MYNZMainz BioMed NV
      02/21/20233:01AMGlobeNewswire Inc.Mainz Biomed Acquires Entire Intellectual Property Portfolio for its Colorectal Cancer Diagnostic Test ProgramNASDAQ:MYNZMainz BioMed NV
      02/15/20233:01AMGlobeNewswire Inc.Mainz Biomed Expands European Commercial Footprint and Enters Markets in Spain and UKNASDAQ:MYNZMainz BioMed NV
      01/20/20234:02PMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:MYNZMainz BioMed NV
      01/18/20233:01AMGlobeNewswire Inc.Mainz Biomed Launches Corporate Health Program in Germany for ColoAlertNASDAQ:MYNZMainz BioMed NV
      01/10/20235:01PMEdgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)NASDAQ:MYNZMainz BioMed NV
      01/09/20236:02AMEdgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:MYNZMainz BioMed NV
      01/03/20233:01AMGlobeNewswire Inc.Mainz Biomed Provides Year-End 2022 Corporate ReviewNASDAQ:MYNZMainz BioMed NV
      12/30/20225:01PMEdgar (US Regulatory)Securities Registration (foreign Private Issuer) (f-3)NASDAQ:MYNZMainz BioMed NV
      12/20/20224:18PMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:MYNZMainz BioMed NV
      12/20/20223:01AMGlobeNewswire Inc.Mainz Biomed Enrolls First Patient in eAArly DETECT Study Evaluating Integration of Novel mRNA Biomarkers into ColoAlertNASDAQ:MYNZMainz BioMed NV
      12/07/20226:25AMTipRanksH.C. Wainwright Sticks to Its Buy Rating for Mainz Biomed B.V. (MYNZ)NASDAQ:MYNZMainz BioMed NV
      12/06/20228:26AMTipRanksMainz Biomed Soars after IRB Approval for Clinical StudyNASDAQ:MYNZMainz BioMed NV
      12/06/20223:01AMGlobeNewswire Inc.Mainz Biomed Announces IRB Approval and Initiation of US Pivotal FDA Clinical StudyNASDAQ:MYNZMainz BioMed NV
      11/29/20228:00AMGlobeNewswire Inc.Mainz Biomed Appoints Amy Levin as Vice President of Regulatory Affairs to Oversee Global Regulatory StrategiesNASDAQ:MYNZMainz BioMed NV
       Showing the most relevant articles for your search:NASDAQ:MYNZ